{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T04:15:13Z","timestamp":1750306513597,"version":"3.41.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,17]]},"DOI":"10.7759\/cureus.86254","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T06:02:43Z","timestamp":1750226563000},"source":"Crossref","is-referenced-by-count":0,"title":["Epstein-Barr Virus (EBV)-Positive Diffuse Large B-Cell Lymphoma in a Young Patient: A Difficult Diagnosis"],"prefix":"10.7759","author":[{"given":"Motona","family":"Kumagai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miyako","family":"Shimasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Shioya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sohsuke","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"EBV-positive diffuse large B-cell lymphoma, not otherwise specified (NOS)","author":"Nakamura S","year":"2017","unstructured":"Nakamura S, Jaffe ES, Swerdlow SH. EBV-positive diffuse large B-cell lymphoma, not otherwise specified (NOS). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (ed): International Agency for Research on Cancer, 2017. 304-6."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio R","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, et al.. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022, 36:1720-48. 10.1038\/s41375-022-01620-2","journal-title":"Leukemia"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-630632","article-title":"EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment","volume":"126","author":"Nicolae A","year":"2015","unstructured":"Nicolae A, Pittaluga S, Abdullah S, et al.. EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment. Blood. 2015, 126:863-72. 10.1182\/blood-2015-02-630632","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70103-8","article-title":"Programmed cell death-1 inhibition in lymphoma","volume":"16","author":"Hawkes EA","year":"2015","unstructured":"Hawkes EA, Grigg A, Chong G. Programmed cell death-1 inhibition in lymphoma. Lancet Oncol. 2015, 16:234-45. 10.1016\/S1470-2045(15)70103-8","journal-title":"Lancet Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202001_22836","article-title":"Clinical features and survival impact of EBV-positive diffuse large B-cell lymphoma with different age cutoffs","volume":"24","author":"Nan FF","year":"2020","unstructured":"Nan FF, Zhang L, Li L, et al.. Clinical features and survival impact of EBV-positive diffuse large B-cell lymphoma with different age cutoffs. Eur Rev Med Pharmacol Sci. 2020, 24:8947-56. 10.26355\/eurrev_202001_22836","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-195792","article-title":"Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired","volume":"114","author":"Ahmadzadeh M","year":"2009","unstructured":"Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, Rosenberg SA. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009, 114:1537-44. 10.1182\/blood-2008-12-195792","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir ME","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008, 26:677-704. 10.1146\/annurev.immunol.26.021607.090331","journal-title":"Annu Rev Immunol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong H","year":"2002","unstructured":"Dong H, Strome SE, Salomao DR, et al.. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002, 8:793-800. 10.1038\/nm730","journal-title":"Nat Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/genes8040116","article-title":"The role of c-MYC in B-cell lymphomas: diagnostic and molecular aspects","volume":"8","author":"Nguyen L","year":"2017","unstructured":"Nguyen L, Papenhausen P, Shao H. The role of c-MYC in B-cell lymphomas: diagnostic and molecular aspects. Genes (Basel). 2017, 8:10.3390\/genes8040116","journal-title":"Genes (Basel)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu556","article-title":"EBV-positive diffuse large B-cell lymphoma in young adults: is this a distinct disease entity?","volume":"26","author":"Hong JY","year":"2015","unstructured":"Hong JY, Yoon DH, Suh C, et al.. EBV-positive diffuse large B-cell lymphoma in young adults: is this a distinct disease entity?. Ann Oncol. 2015, 26:548-55. 10.1093\/annonc\/mdu556","journal-title":"Ann Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00386","article-title":"Tumor-intrinsic PD-L1 signaling in cancer initiation, development and treatment: beyond immune evasion","volume":"8","author":"Dong P","year":"2018","unstructured":"Dong P, Xiong Y, Yue J, Hanley SJ, Watari H. Tumor-intrinsic PD-L1 signaling in cancer initiation, development and treatment: beyond immune evasion. Front Oncol. 2018, 8:386. 10.3389\/fonc.2018.00386","journal-title":"Front Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome","volume":"8","author":"Alsaab HO","year":"2017","unstructured":"Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, Iyer AK. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017, 8:561. 10.3389\/fphar.2017.00561","journal-title":"Front Pharmacol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401572","article-title":"The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity","volume":"193","author":"Ostrand-Rosenberg S","year":"2014","unstructured":"Ostrand-Rosenberg S, Horn LA, Haile ST. The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity. J Immunol. 2014, 193:3835-41. 10.4049\/jimmunol.1401572","journal-title":"J Immunol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4198","article-title":"EBV-positive B-cell lymphomas and lymphoproliferative disorders: review from the perspective of immune escape and immunodeficiency","volume":"10","author":"Satou A","year":"2021","unstructured":"Satou A, Nakamura S. EBV-positive B-cell lymphomas and lymphoproliferative disorders: review from the perspective of immune escape and immunodeficiency. Cancer Med. 2021, 10:6777-85. 10.1002\/cam4.4198","journal-title":"Cancer Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12103052","article-title":"Impact of MYC on anti-tumor immune responses in aggressive B cell non-Hodgkin lymphomas: consequences for cancer immunotherapy","volume":"12","author":"de Jonge AV","year":"2020","unstructured":"de Jonge AV, Mutis T, Roemer MG, Scheijen B, Chamuleau ME. Impact of MYC on anti-tumor immune responses in aggressive B cell non-Hodgkin lymphomas: consequences for cancer immunotherapy. Cancers (Basel). 2020, 12:3052. 10.3390\/cancers12103052","journal-title":"Cancers (Basel)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02264-08","article-title":"c-Myc and Rel\/NF-kappaB are the two master transcriptional systems activated in the latency III program of Epstein-Barr virus-immortalized B cells","volume":"83","author":"Faumont N","year":"2009","unstructured":"Faumont N, Durand-Panteix S, Schlee M, et al.. c-Myc and Rel\/NF-kappaB are the two master transcriptional systems activated in the latency III program of Epstein-Barr virus-immortalized B cells. J Virol. 2009, 83:5014-27. 10.1128\/JVI.02264-08","journal-title":"J Virol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1102277","article-title":"B7-H1, which represses EBV-immortalized B cell killing by autologous T and NK cells, is oppositely regulated by c-Myc and EBV latency III program at both mRNA and secretory lysosome levels","volume":"189","author":"Durand-Panteix S","year":"2012","unstructured":"Durand-Panteix S, Farhat M, Youlyouz-Marfak I, et al.. B7-H1, which represses EBV-immortalized B cell killing by autologous T and NK cells, is oppositely regulated by c-Myc and EBV latency III program at both mRNA and secretory lysosome levels. J Immunol. 2012, 189:181-90. 10.4049\/jimmunol.1102277","journal-title":"J Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/375191-epstein-barr-virus-ebv-positive-diffuse-large-b-cell-lymphoma-in-a-young-patient-a-difficult-diagnosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T06:02:44Z","timestamp":1750226564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/375191-epstein-barr-virus-ebv-positive-diffuse-large-b-cell-lymphoma-in-a-young-patient-a-difficult-diagnosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.86254","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,17]]}}}